Bacterial DnaK reduces the activity of anti-cancer drugs cisplatin and 5FU

Francesca Benedetti,Emmanuel F. Mongodin,Jonathan H. Badger,Arshi Munawwar,Ashley Cellini,Weirong Yuan,Giovannino Silvestri,Carl N. Kraus,Simone Marini,Chozha V. Rathinam,Marco Salemi,Hervé Tettelin,Robert C. Gallo,Davide Zella
DOI: https://doi.org/10.1186/s12967-024-05078-x
IF: 8.44
2024-03-15
Journal of Translational Medicine
Abstract:Chemotherapy is a primary treatment for cancer, but its efficacy is often limited by cancer-associated bacteria (CAB) that impair tumor suppressor functions. Our previous research found that Mycoplasma fermentans DnaK, a chaperone protein, impairs p53 activities, which are essential for most anti-cancer chemotherapeutic responses.
medicine, research & experimental
What problem does this paper attempt to address?